|
Characteristic
|
Adverse events status1
|
Crude hazard ratio [95 % CI]
|
p-value
|
Adjusted hazard ratio [95 % CI]
|
p-value
|
|---|
|
Present
|
Absent
|
|---|
|
Drug regimen
| | | | | | |
|
3TC/AZT −28 days
|
68
|
7
|
1.00
| |
1.00
| |
|
3TC/AZT-3 days
|
28
|
73
|
0.31 [0.20–0.48]
|
<0.001
|
0.30 [0.18–0.48]
|
<0.001
|
|
3TC/AZT/LPV-RTV-28 days
|
50
|
2
|
1.06 [0.74–1.53]
|
0.752
|
1.06 [0.65–1.72]
|
0.817
|
|
Gender
| | | | | |
-
|
|
Female
|
81
|
50
|
1.00
| | | |
|
Male
|
65
|
32
|
1.08 [0.78–1.50]
|
0.629
| | |
|
Type of exposure
| | | | | |
-
|
|
Percutaneous
|
131
|
80
|
1.00
| | | |
|
Mucocutaneous
|
15
|
2
|
1.42 [0.83–2.43]
|
0.197
| | |
|
Age category (yrs)
| | | | | |
-
|
|
18–30
|
101
|
60
|
1.00
| | | |
|
31–40
|
32
|
18
|
1.02 [0.69–1.52]
|
0.921
| | |
|
41–50
|
8
|
2
|
1.28 [0.62–2.62]
|
0.508
| | |
|
>51
|
5
|
2
|
1.14 [0.46–2.80]
|
0.777
| | |
|
Risk assessment
| | | | | | |
|
Low
|
51
|
63
|
1.00
| |
1.00
| |
|
Medium
|
40
|
16
|
1.60 [1.06–2.42]
|
0.027
|
0.95 [0.61–1.49]
|
0.885
|
|
High
|
55
|
3
|
2.12 [1.45–3.10]
|
<0.001
|
0.97 [0.57–1.66]
|
0.922
|
|
Profession
| | | | | |
-
|
|
Nurses
|
51
|
31
|
1.00
| | | |
|
HCS
|
14
|
10
|
0.94 [0.52–1.69]
|
0.832
| | |
|
Laboratory Staff
|
15
|
1
|
1.51 [0.85–2.68]
|
0.162
| | |
|
Medical Doctors
|
46
|
31
|
0.96 [0.65–1.43]
|
0.843
| | |
|
Ward Attendants
|
20
|
9
|
1.11 [0.66–1.86]
|
0.695
| | |
- 1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16) were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval
